NL-OMON37671
Completed
Phase 2
Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory study - S44121 in CPVT
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- catecholaminergic polymorphic ventricular tachycardia
- Sponsor
- Servier R&D Benelux
- Enrollment
- 3
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Male or female patients aged 18 years or more;\- Established diagnosis of CPVT type 1;\- Treatment with beta\-blocker;\- Qualifying ETs meeting a predefined degree of severity and stability of the disease;\- Presence of an ICD for primary or secondary prevention of ventricular arrhythmia implanted at least 3 months prior to pre\-selection
Exclusion Criteria
- •\- Resting ECG with an abnormality that could preclude a proper interpretation of the ECG obtained during the ETs;\- Chronic heart failure;\- Structural congenital heart disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-000579-15-GBInstitut de Recherches Internationales Servier36
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-000579-15-DEInstitut de Recherches Internationales Servier
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1EUCTR2011-000579-15-FIInstitut de Recherches Internationales Servier
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1EUCTR2011-000579-15-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER36
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-000579-15-HUInstitut de Recherches Internationales Servier36